Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Using Na3PO4 to Enhance In vitro Animal Models of Aortic Valve Calcification.

Lerman DA, Prasad S, Alotti N.

Int J Cardiovasc Res. 2016 Jan 7;5(1). doi: 10.4172/2324-8602.1000250.

3.
4.

Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.

Lake JE, Seang S, Kelesidis T, Liao DH, Hodis HN, Stein JH, Currier JS.

HIV Clin Trials. 2015 Oct;16(5):197-206. doi: 10.1179/1945577115Y.0000000006.

5.

Osteoprotegerin, but Not Receptor Activator for Nuclear Factor-κB Ligand, is Associated With Subclinical Coronary Atherosclerosis in HIV-Infected Men.

Ketlogetswe KS, McKibben R, Jacobson LP, Li X, Dobs AS, Budoff M, Witt MD, Palella FJ Jr, Kingsley L, Margolick JB, Post WS, Brown TT.

J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):362-9. doi: 10.1097/QAI.0000000000000725.

6.

Haptoglobin 2-2 genotype is not associated with cardiovascular risk in subjects with elevated glycohemoglobin-results from the Bruneck Study.

Pechlaner R, Kiechl S, Willeit P, Demetz E, Haun M, Weger S, Oberhollenzer F, Kronenberg F, Bonora E, Weiss G, Willeit J.

J Am Heart Assoc. 2014 May 16;3(3):e000732. doi: 10.1161/JAHA.113.000732.

7.

Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6.

Callegari A, Coons ML, Ricks JL, Rosenfeld ME, Scatena M.

J Vasc Res. 2014;51(2):118-31. doi: 10.1159/000358920.

8.

Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor- κ B Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus.

Lambrinoudaki I, Tsouvalas E, Vakaki M, Kaparos G, Stamatelopoulos K, Augoulea A, Pliatsika P, Alexandrou A, Creatsa M, Karavanaki K.

Int J Endocrinol. 2013;2013:102120. doi: 10.1155/2013/102120.

9.

RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.

Samelson EJ, Miller PD, Christiansen C, Daizadeh NS, Grazette L, Anthony MS, Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP.

J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043.

10.

MicroRNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms.

Goettsch C, Hutcheson JD, Aikawa E.

Circ Res. 2013 Mar 29;112(7):1073-84. doi: 10.1161/CIRCRESAHA.113.300937. Erratum in: Circ Res. 2013 Nov 8;113(11):e106.

11.
12.

RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-α.

Deuell KA, Callegari A, Giachelli CM, Rosenfeld ME, Scatena M.

J Vasc Res. 2012;49(6):510-21. doi: 10.1159/000341216.

13.

Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients.

Hwang JJ, Wei J, Abbara S, Grinspoon SK, Lo J.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):359-63. doi: 10.1097/QAI.0b013e31826a6c16.

14.

Evaluation of RANKL/OPG Serum Concentration Ratio as a New Biomarker for Coronary Artery Calcification: A Pilot Study.

Mohammadpour AH, Shamsara J, Nazemi S, Ghadirzadeh S, Shahsavand S, Ramezani M.

Thrombosis. 2012;2012:306263. doi: 10.1155/2012/306263.

15.

Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients.

Ozkok A, Caliskan Y, Sakaci T, Erten G, Karahan G, Ozel A, Unsal A, Yildiz A.

Clin J Am Soc Nephrol. 2012 Jun;7(6):965-73. doi: 10.2215/CJN.11191111.

16.

Regulatory mechanisms in vascular calcification.

Sage AP, Tintut Y, Demer LL.

Nat Rev Cardiol. 2010 Sep;7(9):528-36. doi: 10.1038/nrcardio.2010.115. Review.

17.

Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality.

Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF Jr, Rong J, Corey D, Hoffmann U, Fox CS, Vasan RS, Benjamin EJ, O'Donnell CJ, Kathiresan S.

Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1849-54. doi: 10.1161/ATVBAHA.109.199661.

18.

Increased bone resorption is associated with increased risk of cardiovascular events in men: the MINOS study.

Szulc P, Samelson EJ, Kiel DP, Delmas PD.

J Bone Miner Res. 2009 Dec;24(12):2023-31. doi: 10.1359/jbmr.090531.

Items per page

Supplemental Content

Support Center